MEDANTAHealthcare

Global Health Limited

Hospital · ISIN INE474Q01031 · BSE 543654 · NSE EQ · FV ₹2
Last price
₹1,424
+1.38%today
What this company does

Global Health Limited operates in Hospital, part of the Healthcare sector. It booked ₹1,304 cr of revenue in its latest quarter (Q1 FY27) and kept 12.2% of sales as profit. It is the 6th largest of 9 Hospital companies we track, by market value.

Their stated mission

is to deliver world-class, patient-centric, integrated and a sustainable, large-format healthcare platform.

In the report:
58out of 100
Equitytale Health Score
Mixed

Healthier than 58% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
50

At close. Not part of the score.

Profitability & returns61

How much profit it earns on the money it employs

Balance sheet47

How much it owes, and whether earnings cover the interest

Cash quality63

Whether reported profit actually arrives as cash

Growth & consistency77

Whether sales and profit have grown, and how steadily

Valuation23

What today's price implies, against our models or its peers

Governance & risk86

How much of the promoters' stake is pledged, and how much they hold

Is this company doing well?
not investment advice
Looks broadly healthyPriced in line with peers
Strengths
Makes a profit
Sales up 27% vs last year
No promoter shares pledged
Strong 16% return on equity
Turns profit into real cash
Watch-outs
None flagged from our data

What if I invest in MEDANTA?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹1,424 +1.38%
latest close · 2026-09-17
52-wk low ₹1,32342 sessions so far52-wk high ₹1,544
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio60.2High
LowAverageHigh
P/B ratio9.66High
Below bookModerateHigh
EV / EBITDA31.8High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity16.0%Strong
WeakFairStrong ▸15%
Return on capital18.2%Strong
WeakFairStrong
Net margin12.2%Decent
ThinDecentStrong
EBITDA margin23.7%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.30Comfortable
LowModerateHigh ▸1
Interest cover9.0×Strong
RiskyOkayStrong ▸5×
Current ratio2.67Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹38,273 cr
Book value
₹147
EPS
₹5.91
latest quarter
Net debt
₹1,063 cr
owes more than its cash
Enterprise value
₹39,336 cr
EBITDA
₹1,236 cr
annualised
EBIT
₹960 cr
annualised
Operating margin
18.4%
Return on assets
10.8%
Earnings yield
1.66%
P/S
7.34
Sales / share
₹194.1
Tax rate
26.3%
Face value
₹2
Shares
26.9 cr
Working capital
₹1,048 cr
Current assets
₹1,675 cr
Current liabilities
₹627 cr
Delivery %
49.7%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2025 report & filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹149₹243, midpoint ₹201

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹1,304 cr
Other Income₹22 cr
Total Income₹1,326 cr
Cost of Materials₹257 cr
Purchases of Stock-in-Trade₹41 cr
Inventory Change (±)₹-4 cr
Employee Benefit Expense₹319 cr
Finance Costs₹27 cr
Depreciation & Amortisation₹69 cr
Other Expenses₹404 cr
Total Expenses₹1,113 cr
Profit before Tax₹213 cr
Tax Expense₹56 cr
Net Profit₹157 cr
Net margin on total income11.9%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹294 cr22.2%
Employee benefit expense₹319 cr24.1%
Finance costs₹27 cr2.0%
Depreciation & amortisation₹69 cr5.2%
Other expenses₹404 cr30.4%
Tax expense₹56 cr4.2%
Profit for the period₹157 cr11.9%
Total income ₹1,326 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue1,121 cr1,159 cr1,304 cr
Total income1,143 cr1,196 cr1,326 cr
Expenses986 cr1,009 cr1,113 cr
Profit before tax120 cr187 cr213 cr
Tax25 cr46 cr56 cr
Net profit (owners' share)95 cr144 cr159 cr
Net margin (owners' share, on revenue)8.5%12.4%12.2%
EPS (₹)3.545.365.91
YoY (latest quarter): total income +26.2% · net profit -0.2%
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹5,905 cr
Shareholder equity
₹3,962 cr
parent shareholders
Total debt
₹1,190 cr
Cash
₹127 cr
Cash flow · H1 FY26
Operating
₹329 cr
Investing
₹46 cr
Financing
₹154 cr
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,769₹1.26 L cr54.3
Max Healthcare Institute Limited₹1,037₹1.01 L cr78.1
Manipal Health Enterprises Limited₹722₹85,125 cr92.0
Fortis Healthcare Limited₹886₹66,897 cr62.8
Aster DM Quality Care Limited₹761₹39,412 cr613.4
Global Health Limitedthis company₹1,424₹38,273 cr60.2
Narayana Hrudayalaya Ltd.₹1,869₹38,187 cr45.8
Krishna Institute of Medical Sciences Limited₹792₹33,258 cr190.3
Dr. Agarwal's Health Care Limited₹500₹15,855 cr87.4
Same industry · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
0.04%
trailing 12 months
Dividend / share (TTM)
₹0.5
Last dividend
₹0.5
ex 14 Aug 2026
ActionDetailEx-date
Dividend₹0.5 / share14 Aug 2026
Dividend₹0.5 / share22 Aug 2025
Who owns it · 2026-06-30
No pledge
Promoter
33.0%
FII / Foreign
9.5%
DII / Domestic
16.9%
Retail / others
40.6%
Promoter stake down 0.1% over the last 12 quarters.
Smart-money activity
Bulk / block deals
short · NSE8424 Jul 26
SoldSUNIL SACHDEVA · NSE10.00 L @ ₹1,22525 May 26
BoughtHDFC MUTUAL FUND · NSE10.00 L @ ₹1,22525 May 26
Stake changes
BoughtInvesco Mutual Fund→ 5.02% · 10.02 L20 Feb 26
BoughtSunil Sachdeva→ 11.16%30 Sep 25
BoughtSunil Sachdeva→ 11.16%30 Sep 25
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 16 Sep 2026
See the official result
1
To consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, the Audited Consolidated Financial Statements for the financial year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon.
Backed by 100% of shareholders other than promotersneeded 50%
15.12 cr votes for, 278 against · 0% of mutual funds and other big investors said no
2
To declare final dividend of ₹ 0.50/- per Equity Share for the financial year ended March 31, 2026
Backed by 100% of shareholders other than promotersneeded 50%
15.12 cr votes for, 837 against · 0% of mutual funds and other big investors said no
3
To appoint a Director in place of Mr. Pankaj Sahni (DIN: 07132999) who retires by rotation and being eligible, offers himself for re-election.
Backed by 100% of shareholders other than promotersneeded 50%
15.07 cr votes for, 5.57 L against · 1% of mutual funds and other big investors said no
4
To approve remuneration of M/s. Ramanath Iyer & Co., Cost Auditors of the Company for Financial Year 2026-27.
Backed by 100% of shareholders other than promotersneeded 50%
15.12 cr votes for, 421 against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 35 named members
owning 33.0% between them · as of 2026-06-30
Naresh Trehan33.00%
Afsan Health Resort Private Limitedno shares
Aroon Purieno shares
Evergreen Securities Private Limitedno shares
IFANFLEX Private Limitedno shares
IFAN Global, Inc.no shares
IFAN Global India Private Limitedno shares
Insaniyatno shares
Business done with them
FY2025 · 1 of the group
The company paid ₹26 cr to companies in the promoter group last year — about 0.7% of its ₹3,692 cr revenue.
Dr. Naresh Trehan
Other payments to them · Salaries and other benefits
also owns 33.00% of the company
₹26 cr
company paid

The company also transacted with 27 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.